Altimmune (ALT) Amortizatization of Intangibles (2016 - 2026)
Altimmune (ALT) posted quarterly Amortizatization of Intangibles of $870000.0 for Q1 2026, up 26.82% year-over-year from $686000.0 in Q1 2025, and down 4.5% quarter-over-quarter from $911000.0 in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends
Altimmune (ALT) has reported Amortizatization of Intangibles for 9 consecutive years, with $870000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 26.82% year-over-year to $870000.0; the TTM figure through Mar 2026 stood at $2.4 million (down 32.23% YoY), while the FY2025 annual figure was $2.2 million, down 42.23% from the prior year.
- Amortizatization of Intangibles eased to $870000.0 in Q1 2026 per ALT's latest filing, from $911000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.1 million in Q2 2024 and bottomed at $196000.0 in Q3 2025.
- Historically, Amortizatization of Intangibles has averaged $724230.8 across 4 years, with a median of $695000.0 in 2023.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles jumped 104.37% — and 2025, when it plunged 79.98%.
- Altimmune's Amortizatization of Intangibles stood at $695000.0 in 2023, then climbed by 17.84% to $819000.0 in 2024, then grew by 11.23% to $911000.0 in 2025, then fell by 4.5% to $870000.0 in 2026.
- Business Quant data shows ALT's Amortizatization of Intangibles at $870000.0 in Q1 2026, $911000.0 in Q4 2025, and $196000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - | 984,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 984,000.00 |
| Mar 31, 2026 | 870,000.00 |
| Dec 31, 2025 | 911,000.00 |
| Sep 30, 2025 | 196,000.00 |
| Jun 30, 2025 | 431,000.00 |
| Mar 31, 2025 | 686,000.00 |
| Dec 31, 2024 | 819,000.00 |
| Sep 30, 2024 | 979,000.00 |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 983,000.00 |
| Dec 31, 2023 | 695,000.00 |
| Sep 30, 2023 | 669,000.00 |
| Jun 30, 2023 | 626,000.00 |
| Mar 31, 2023 | 481,000.00 |
| Sep 30, 2020 | 10,406.00 |
| Jun 30, 2020 | 12,025.00 |
| Mar 31, 2020 | 13,851.00 |
| Dec 31, 2019 | 11,836.00 |
| Sep 30, 2019 | 28,084.00 |
| Jun 30, 2019 | 14,836.00 |